CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced the appointment of Dymeka Harrison, MBA, as its Chief Commercial Officer. In this role, Harrison will develop and execute global clinical commercial strategy, champion a broader understanding of comprehensive genomic profiling (CGP) and promote Foundation Medicine’s proven portfolio of testing services.
Foundation Medicine’s clinical commercial team works across the oncology ecosystem to support physicians seeking personalized treatment options for their patients, while collaborating with third-party payers to ensure appropriate diagnostic utilization. Harrison will lead the team in strengthening existing customer relationships and establishing new partnerships, with the goal of expanding patient access to evidence-driven treatment decisions.
With nearly two-decades of experience in the diagnostics industry, Harrison joins Foundation Medicine from Abbott Laboratories, where she most recently served as Head of Strategic Marketing, overseeing global marketing efforts for the company’s Rapid Diagnostics Division. At Abbott Laboratories, she was instrumental in developing and implementing innovative strategies that accelerated product launches and business opportunities, while providing direct leadership over several key commercial areas. Harrison previously held roles at QIAGEN, bioMérieux, and Thermo Fisher.
“We are committed to achieving a future where genomic profiling is indispensable to cancer care,” said Brian Alexander, MD, MPH, chief executive officer at Foundation Medicine. “Dymeka’s purpose-driven leadership approach, and extensive experience in diagnostics will enable Foundation Medicine to continue providing physicians, researchers, and other key partners with the patient-focused solutions they need to meaningfully impact the lives of people living with cancer.”
Harrison will spearhead Foundation Medicine’s future innovative customer collaborations, providing the company’s broad range of partners with the products, programs, and services necessary to match patients with personalized treatment solutions. She will focus on breaking down barriers to patient access and exploring new opportunities to work on a systemic level with health systems, academic medical centers, and community practices. Harrison will also continue to build Foundation Medicine’s commercial leadership through a strong presence in the oncology community.
“Foundation Medicine is both an industry pioneer and a market leader, and the company’s dedication to innovation and next-level patient care is palpable,” said Harrison. “I am thrilled to be joining such a bold and strategic team, forging partnerships that center patients in all that we do. I am eager to continue providing care teams and researchers with tools to improve treatment pathways for their patients.”
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.
Source: Foundation Medicine